慢性血栓栓塞性肺动脉高压发病机制新进展:从基础到临床  被引量:2

Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension:from Bench to Bedside

在线阅读下载全文

作  者:黄志华 罗勤[1] 赵智慧[1] 赵青[1] 柳志红[1] HUANG Zhihua;LUO Qin;ZHAO Zhihui;ZHAO Qing;LIU Zhihong(Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)

机构地区:[1]中国医学科学院,北京协和医学院,国家心血管病中心阜外医院,北京100037

出  处:《心血管病学进展》2022年第4期297-300,共4页Advances in Cardiovascular Diseases

基  金:中国医学科学院临床与转化医学研究基金(2020-I2M-C&T-B-055,2021-I2M-C&T-B-032);北京市自然科学基金(7202168)。

摘  要:慢性血栓栓塞性肺动脉高压(CTEPH)属于肺动脉高压分型的第四大类,是一种自然预后极差的慢性进展性疾病。CTEPH通常被认为是急性肺血栓栓塞症(APTE)的一种长期并发症,但研究表明部分CTEPH患者无明确的APTE既往史。因此,阐明CTEPH的发病机制,对于认识CTEPH的发生发展过程、指导疾病诊治具有重要意义。现围绕病理生理机制和靶向药物等临床治疗策略方面,总结CTEPH发病机制新进展,为CTEPH诊治提供理论依据。Chronic thromboembolic pulmonary hypertension(CTEPH)belongs to the fourth category of pulmonary hypertension,and it is a chronic progressive disease with a poor natural prognosis.CTEPH is generally considered to be a long-term complication of acute pulmonary thromboembolism(APTE),but studies have shown that some patients with CTEPH do not have a history of APTE.Therefore,clarifying the pathogenesis of CTEPH is of great significance for understanding the occurrence and course of CTEPH and guiding disease diagnosis and treatment.This article summarizes the advances in the pathogenesis of CTEPH from the perspectives of pathophysiology and clinical therapeutic strategies such as targeted drugs,to provide a theoretical basis for the diagnosis and treatment of CTEPH.

关 键 词:血栓栓塞 肺高压 发病机制 病理生理 靶向药物 

分 类 号:R54[医药卫生—心血管疾病]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象